Literature DB >> 28663190

Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic Retinopathy: Cross-sectional Analyses of Baseline Data of the EUROCONDOR Project.

Ana Rita Santos1,2, Luísa Ribeiro1, Francesco Bandello3, Rosangela Lattanzio3, Catherine Egan4, Ulrik Frydkjaer-Olsen5, José García-Arumí6, Jonathan Gibson7, Jakob Grauslund5, Simon P Harding8, Gabriele E Lang9, Pascale Massin10, Edoardo Midena11, Peter Scanlon12, Stephen J Aldington12, Sílvia Simão1, Christian Schwartz1, Berta Ponsati13, Massimo Porta14, Miguel Ângelo Costa1, Cristina Hernández15, José Cunha-Vaz16, Rafael Simó17.   

Abstract

This cross-sectional study evaluated the relationship between 1) functional and structural measurements of neurodegeneration in the initial stages of diabetic retinopathy (DR) and 2) the presence of neurodegeneration and early microvascular impairment. We analyzed baseline data of 449 patients with type 2 diabetes enrolled in the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) study (NCT01726075). Functional studies by multifocal electroretinography (mfERG) evaluated neurodysfunction, and structural measurements using spectral domain optical coherence tomography (SD-OCT) evaluated neurodegeneration. The mfERG P1 amplitude was more sensitive than the P1 implicit time and was lower in patients with Early Treatment of Diabetic Retinopathy Study (ETDRS) level 20-35 than in patients with ETDRS level <20 (P = 0.005). In 58% of patients, mfERG abnormalities were present in the absence of visible retinopathy. Correspondence between SD-OCT thinning and mfERG abnormalities was shown in 67% of the eyes with ETDRS <20 and in 83% of the eyes with ETDRS level 20-35. Notably, 32% of patients with ETDRS 20-35 presented no abnormalities in mfERG or SD-OCT. We conclude that there is a link between mfERG and SD-OCT measurements that increases with the presence of microvascular impairment. However, a significant proportion of patients in our particular study population (ETDRS ≤35) had normal ganglion cell-inner plexiform layer thickness and normal mfERG findings. We raise the hypothesis that neurodegeneration may play a role in the pathogenesis of DR in many but not in all patients with type 2 diabetes.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2017        PMID: 28663190     DOI: 10.2337/db16-1453

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  38 in total

Review 1.  Retinal Neurodegeneration as an Early Manifestation of Diabetic Eye Disease and Potential Neuroprotective Therapies.

Authors:  Sidra Zafar; Mira Sachdeva; Benjamin J Frankfort; Roomasa Channa
Journal:  Curr Diab Rep       Date:  2019-02-26       Impact factor: 4.810

2.  Retinal vasculature-function correlation in non-proliferative diabetic retinopathy.

Authors:  Yunkao Zeng; Dan Cao; Dawei Yang; Xuenan Zhuang; Yunyan Hu; Miao He; Honghua Yu; Jun Wang; Cheng Yang; Liang Zhang
Journal:  Doc Ophthalmol       Date:  2019-09-24       Impact factor: 2.379

Review 3.  Spermine oxidase: A promising therapeutic target for neurodegeneration in diabetic retinopathy.

Authors:  S Priya Narayanan; Esraa Shosha; Chithra D Palani
Journal:  Pharmacol Res       Date:  2019-06-15       Impact factor: 7.658

4.  Somatostatin and diabetic retinopathy: an evolving story.

Authors:  Olga Simó-Servat; Cristina Hernández; Rafael Simó
Journal:  Endocrine       Date:  2018-02-20       Impact factor: 3.633

Review 5.  [Unmet research and developmental needs in ophthalmology : A consensus-based road map of the European Vision Institute for 2019-2025].

Authors:  C Cursiefen; F Cordeiro; J Cunha-Vaz; T Wheeler-Schilling; H P N Scholl
Journal:  Ophthalmologe       Date:  2019-09       Impact factor: 1.059

Review 6.  Diabetic retinal neurodegeneration as a form of diabetic retinopathy.

Authors:  Deepak Soni; Pradeep Sagar; Brijesh Takkar
Journal:  Int Ophthalmol       Date:  2021-05-06       Impact factor: 2.031

7.  Assessment of retinal neurodegeneration with spectral-domain optical coherence tomography: a systematic review and meta-analysis.

Authors:  Ziqi Tang; Ming Yan Chan; Wai Yin Leung; Ho Yeung Wong; Ching Man Ng; Victor T T Chan; Raymond Wong; Jerry Lok; Simon Szeto; Jason C K Chan; Clement C Tham; Tien Y Wong; Carol Y Cheung
Journal:  Eye (Lond)       Date:  2020-06-24       Impact factor: 3.775

8.  Microperimetry and mfERG as functional measurements in diabetic macular oedema undergoing intravitreal ranibizumab treatment.

Authors:  Ana Rita Santos; Miguel Raimundo; Dalila Alves; Marta Lopes; Sérgio Pestana; João Figueira; José Cunha-Vaz; Rufino Silva
Journal:  Eye (Lond)       Date:  2020-07-02       Impact factor: 3.775

9.  The neuroscience of diabetic retinopathy.

Authors:  David A Antonetti
Journal:  Vis Neurosci       Date:  2021-01-18       Impact factor: 3.241

10.  Diabetic Macular Edema Treated with 577-nm Subthreshold Micropulse Laser: A Real-Life, Long-Term Study.

Authors:  Luisa Frizziero; Andrea Calciati; Tommaso Torresin; Giulia Midena; Raffaele Parrozzani; Elisabetta Pilotto; Edoardo Midena
Journal:  J Pers Med       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.